500% Gain In Premarket Session - Here's Why Precision Medicine OpGen Stock Is Soaring

OpGen Inc OPGN stock is trading higher following two SEC filings from the precision medicine company.

The company has received an advanced payment of €750,000 related to the sale of certain Unyvero A50 systems by Curetis to a strategic partner.

The strategic partner may, in its discretion, purchase additional Unyvero A50 systems from Curetis while the parties continue to pursue a potential strategic transaction.

The company intends to use the advance payment to fund Curetis’ and Ares Genetics’ operations while negotiating with the strategic partner.

OpGen also announced a Preferred Stock Purchase Agreement. It signed an agreement with a certain investor to acquire 1,000 shares priced at $1,000 each, with gross proceeds of $1 million. 

The Private Placement was conducted in connection with the negotiation of a potential strategic transaction involving the company and the Investor. 

OpGen stock is gaining on heavy volume, with a session volume of 14.9 million shares traded, compared to the trailing 100-day volume of 2.24 million shares.

Price Action: OPGN shares are up 578.6% at $2.28 during the premarket session on the last check Thursday.